The World Federation of Neurosurgical Societies (WFNS) Innovation & Technology Committee has announced a landmark collaboration with Time Medical International Ventures (India) Pvt. Ltd. (Time Medical India), a wholly owned subsidiary of Fischer Medical Ventures Limited. The announcement was made on May 14, 2026, marking a significant milestone in advancing innovation in global neurosurgical care.

A Historic First for the WFNS Innovation & Technology Committee

For the first time in its history, the WFNS Innovation & Technology Committee has formally welcomed an industry partner into its innovation ecosystem. This development reflects the growing importance of collaboration between neurosurgical leadership and advanced medical technology providers. The partnership is designed to accelerate the development and dissemination of cutting-edge neurosurgical technologies, support global training and capacity-building initiatives, and facilitate meaningful collaboration between clinicians and industry innovators.

Key focus areas of the collaboration include:

• Cutting-edge neurosurgical technologies
• Advanced medical imaging solutions
• Global training and knowledge-sharing initiatives
• Technology transfer initiatives in emerging markets
• Improvement of patient outcomes across diverse healthcare systems

Partnership Overview

The following table summarises the key details of this collaboration:

Technology Capabilities of Time Medical India

Time Medical International Ventures (India) Pvt. Ltd. has been recognised for its contributions in advanced medical imaging and neurosurgical technologies. Its portfolio includes:

• Single-room intraoperative MRI operation suites
• Exoscope and visualisation technologies
• Specialised MRI solutions for brain aneurysm and ICAD screening

The association is expected to create a strong platform for innovation-driven advancements in neurosurgery and neuroimaging.

Leadership Perspectives

Prof. Dr. Iype Cherian, Chairperson of the WFNS Innovation & Technology Committee, commented on the significance of the partnership:

"For the first time in the history of the WFNS Innovation Committee, we are opening our doors to the private sector. This partnership reflects our commitment to bringing together the most innovative minds and transformative technologies to advance neurosurgical care globally. Time Medical International Ventures has demonstrated exceptional capabilities in innovation and clinical technology, making them an ideal partner as we work collectively to shape the future of neurosurgery."

He further added:

"This collaboration will help champion the development and global dissemination of cutting-edge neurosurgical solutions, facilitate knowledge exchange between leading neurosurgeons and industry experts, and support training and technology transfer initiatives in emerging markets. We believe this partnership will set a new benchmark for industry collaboration within global neurosurgical governance."

Svetlana Rao, Director of Time Medical International Ventures (India) Pvt. Ltd., said:

"We are honoured to be welcomed as an Industry Partner by the WFNS Innovation & Technology Committee. This collaboration represents a shared vision of advancing neurosurgical excellence through innovation, technology, and global cooperation. As a wholly owned subsidiary of Fischer Medical Ventures Limited, we remain committed to supporting transformative healthcare solutions that improve accessibility, precision, and patient outcomes across diverse healthcare systems."

Setting a New Benchmark for Global Neurosurgical Governance

The WFNS Innovation & Technology Committee expressed confidence that this landmark partnership will set a new benchmark for the role of industry within global neurosurgical governance and serve as a model for future collaborations. The Committee reaffirmed its commitment to ensuring that the engagement remains impactful, transparent, and guided by the highest ethical standards. Both organisations aim to shape the future of neurosurgery through shared vision, collaboration, innovation, and an enduring commitment to improving patient outcomes worldwide.

Fischer medical ventures Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The filing demonstrates the company's commitment to maintaining transparency and regulatory compliance in its securities operations.

Regulatory Filing Details

The compliance certificate covers the quarter ended March 31, 2026, and was filed under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Balaji Gandla submitted the documentation to both major stock exchanges on April 9, 2026.

RTA Confirmation Certificate

Adroit Corporate Services Pvt. Ltd., serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 1, 2026. The RTA certificate validates several critical compliance aspects for the quarter ended March 31, 2026.

The confirmation covers key operational areas including:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialization have been mutilated and cancelled after due verification
• Depository names have been substituted in the register of members as registered owners within the mandated 15-day period

Company Information

Compliance Significance

The quarterly compliance certificate represents a mandatory regulatory requirement ensuring proper handling of dematerialized securities. The filing confirms that Fischer Medical Ventures Limited maintains appropriate systems and processes for securities management through its appointed RTA.

The documentation demonstrates the company's adherence to SEBI regulations governing depositories and participants, providing assurance to investors and regulatory authorities about proper securities handling procedures. This routine compliance filing reflects the company's commitment to maintaining regulatory standards in its operations.